We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Celldex Therapeutics Inc (CLDX) USD0.001

Sell:$31.50 Buy:$41.00 Change: $1.93 (5.13%)
Market closed |  Prices as at close on 3 December 2021 | Switch to live prices |
Change: $1.93 (5.13%)
Market closed |  Prices as at close on 3 December 2021 | Switch to live prices |
Change: $1.93 (5.13%)
Market closed |  Prices as at close on 3 December 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Celldex Therapeutics, Inc. is a biopharmaceutical company. The Company is engaged in developing therapeutic monoclonal and bispecific antibodies. The Company's drug candidates include antibody-based therapeutics to improve the lives of patients with inflammatory diseases and many forms of cancer. The Company is engaged in the research and development of CDX-015, CDX-1140 and CDX-527. CDX-0159, a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity, has completed a Phase Ia study in healthy subjects. CDX-1140, an agonist monoclonal antibody targeted to CD40, a key activator of immune response, is being studied in a Phase I study. CDX-527 is the first candidate from Celldex's bispecific antibody platform. CDX-527 is a bispecific antibody that uses the Company's anti-PD-L1 and CD27 human antibodies to couple CD27 co-stimulation with blockade of the PD-L1/PD-1 pathway, and Company has initiated a Phase I study in advanced solid tumors.

Contact details

53 Frontage Rd Ste 220
United States
+1 (908) 2007500

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$1.68 billion
Shares in issue:
46.66 million
United States
US dollar

Key personnel

  • Sam Martin
    Chief Financial Officer, Senior Vice President, Secretary
  • Tibor Keler
    Executive Vice President and Chief Scientific Officer
  • Freddy Jimenez
    Senior Vice President, General Counsel
  • Sarah Cavanaugh
    Senior Vice President - Corporate Affairs and Administration
  • Elizabeth Crowley
    Senior Vice President, Chief Product Development Officer
  • Margo Heath-Chiozzi
    Senior Vice President - Regulatory Affairs
  • Ronald Pepin
    Senior Vice President and Chief Business Officer
  • Richard Wright
    Senior Vice President, Chief Commercial Officer
  • Diane Young
    Senior Vice President, Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.